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Abstract
Background: Standard survival analysis fails to give insight into what happens to a patient after a first outcome
event (like first relapse of a disease). Multi-state models are a useful tool for analyzing survival data when different
treatments and results (intermediate events) can occur. Aim of this study was to implement a multi-state model on
data of patients with rectal cancer to illustrate the advantages of multi-state analysis in comparison to standard
survival analysis.
Methods: We re-analyzed data from the RCT FOGT-2 study by using a multi-state model. Based on the results we
defined a high and low risk reference patient. Using dynamic prediction, we estimated how the survival probability
changes as more information about the clinical history of the patient becomes available.
Results: A patient with stage UICC IIIc (vs UICC II) has a higher risk to develop distant metastasis (DM) or
both DM and local recurrence (LR) if he/she discontinues chemotherapy within 6 months or between 6 and
12 months, as well as after the completion of 12 months CTx with HR 3.55 (p = 0.026), 5.33 (p = 0.001) and 3.
37 (p < 0.001), respectively. He/she also has a higher risk to die after the development of DM (HR 1.72, p = 0.
023). Anterior resection vs. abdominoperineal amputation means 63% risk reduction to develop DM or both
DM and LR (HR 0.37, p = 0.003) after discontinuation of chemotherapy between 6 and 12 months. After
development of LR, a woman has a 4.62 times higher risk to die (p = 0.006). A high risk reference patient has
an estimated 43% 5-year survival probability at start of CTx, whereas for a low risk patient this is 79%. After
the development of DM 1 year later, the high risk patient has an estimated 5-year survival probability of 11%
and the low risk patient one of 21%.
Conclusions: Multi-state models help to gain additional insight into the complex events after start of
treatment. Dynamic prediction shows how survival probabilities change by progression of the clinical history.
Keywords: Multi-state model (msm), Dynamic prediction, Rectal cancer (RC), Local recurrence (LR), Distant
metastasis (DM)
* Correspondence: giulia.manzini@uniklinik-ulm.de
1Department of General and Visceral Surgery, University Hospital of Ulm,
Albert-Einstein-Allee 23, 89073 Ulm, Germany
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Manzini et al. BMC Medical Research Methodology  (2018) 18:23 
DOI 10.1186/s12874-018-0476-z
Background
The medical history of a cancer patient is very complex
and often includes different intermediate events, as for ex-
ample the development of distant metastasis (DM) or
local recurrence (LR) after surgery of the primary tumor,
which plays a central role in influencing the survival prog-
nosis. Standard survival analysis can analyze separately dif-
ferent endpoints but fails to give insight into what
happens to a patient after a first event [1]. Multi-state
models are an extension of classical survival analysis
which allows adjustment to the prediction of survival dur-
ation of the patient in the course of time by incorporating
new information regarding the progression of the medical
history and to better understand how prognostic factors
influence the different phases of the disease/recovery
process [2]. A multi-state model (msm) is a model for
time-to-event data in which all individuals start at one or
possibly more starting states and eventually may end up in
one (or more) absorbing or final state(s). In between,
intermediate states can be visited, possibly more than
once. Some individuals are censored before they reach an
absorbing state [2, 3]. For example, the starting state could
represent the time of discovery of a disease, the final state
usually is death, intermediate states reflect all relevant
treatments or disease stages or generally clinical events
between starting state and final state. These models are
very helpful in clinical decision making because they allow
the prognosis of the patient to be updated according to
the progression of the disease.
The course of the events between diagnosis of cancer, the
many possible intermediate events like a surgical interven-
tion, the development of metastasis, the commencement of
chemotherapy (CTx) and, in the worst case, the death of a
patient as final event, can be described very well by a multi-
state model. This relatively new method for analysis of sur-
vival data is still not well known in the medical world. The
aim of this study was to implement a multi-state model on
data of patients with rectal cancer to illustrate the advan-
tages of multi-state analysis in comparison to standard sur-
vival analysis.
The prognosis of rectal cancer has been improved signifi-
cantly over the past decades as reported by De Angelis et
al.; in 2014 with an increase in the 5-year overall survival
from 1999 to 2001 of 52.1% (51.6–52.6) to 2005–07 of
57.6% (57.1–58.1), respectively [4]. This can be explained
by the improvement of surgical techniques with the intro-
duction of total mesorectal excision (TME) [5–11] and of
MRI as diagnostic instrument [12] as well as multidisciplin-
ary treatment with better neoadjuvant radiochemotherapy
and adjuvant CTx [13]. Regarding locally advanced rectal
cancer (stage II and III) this multidisciplinary work in-
creased the 5-year cause-specific survival rates from 53.4%
for patients treated between 1981 and 1986 to 89.8% for
patients treated between 2007 and 2011 [13].
As the clinical history of rectal cancer patients can be
well described with a msm, we analyzed the outcomes of
patients from the multicentric FOGT-2 trial [14] using a
msm in order to assess the influence of certain prognostic
factors like age, gender, body mass index (BMI), UICC
tumor stage, tumor grade and type of operation on different
phases of the disease/recovery process of the patient and to
obtain more accurate predictions of long-term survival than
with a standard survival model by adjusting the initial pre-
diction in the course of time by incorporating new informa-
tion regarding intermediate events [2] like completion and
duration of the adjuvant CTx or development of DM. So
far, clinical applications of multi-state models have been
limited because of the difficulties of the analysis [2]. Putter
et al. published in 2006 the first re-analysis of Breast cancer
data by using a multi-state model, clearly showing the
added value of this kind of analysis [1]. We present the first
application of a multi-state model to data from patients
with locally advanced rectal cancer with the aim to intro-
duce the advantages of this type of analysis in the research
field of abdominal surgery.
Methods
Aim of the study
The aim of this study was to implement the multi-state
model on data of patients with rectal cancer in order to
illustrate the advantage of multi-state analysis in com-
parison to standard survival analysis.
Included patients
We re-analyzed data from the multicentric RCT FOGT-
2 [14] by using a msm. The FOGT-2 trial was set up to
optimize adjuvant CTx of locally advanced RC (UICC
stage II-pT3/T4 pN0 M0 or III-pT1–4 pNpos M0). A
total of 796 patients were randomly assigned after pri-
mary surgery to three treatment arms: 5-FU alone, 5-FU
+ folinic acid (FA), and 5-FU + interferon-alpha (INF-α),
arm A, B, and C, respectively. The complete postopera-
tive adjuvant CTx treatment, irrespective of the
randomization arm to which the patient was assigned,
lasted 12 months. The following baseline covariates were
considered: age, gender, BMI, UICC tumor stage, tumor
grade and operation type (abdominoperineal amputation
vs. anterior resection). In our msm study n = 471
patients (59.2%) were included for whom duration of the
adjuvant CTx was documented and the set of all baseline
covariates was complete (Additional file 1: Appendix A).
Ethics For the present analysis the original data set of the
FOGT-2 trial was used. This set is stored in anonymous
form at the Clinic of General and Visceral Surgery and is
readily available for access as Excel table. The original
study (FOGT-2) conformed to the International Confer-
ence on Harmonisation/WHO Good clinical practice and
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was approved by the Ethics Committee of the University
of Ulm (#87/91). All patients gave informed consent to
participate, were informed and agreed to subsequent
anonymous data analysis. Therefore no additional ethics
approval was required for the present evaluation.
Statistical analysis
Baseline characteristics were summarized as median
[range] for continuous variables and frequencies and per-
centages for categorical variables, respectively. For the
whole analysis, time was measured since date of com-
mencement of adjuvant CTx. All outcomes were estimated
by means of a multi-state model (see Appendix for a gen-
eral explanation of the multi-state methodology). The
quantities of interest in the multi-state model were esti-
mated in R, version 3.3.0 with library ˋmstate´ (http://
www.r-project.org) [2, 15].
The multi-state model
We designed a multi-state model composed of 8 states
(Additional file 1: Appendix A, Figure A1), i.e. state 1:
Event-free and alive after having received CTx for less than
6 months (starting state), state 2: Event-free and alive after
at least 6 months CTx but less than 12 months (intermedi-
ate state), state 3: Event-free and alive after completion of
the 12 months of CTx program (intermediate state), state 4:
Early discontinuation (discontinuation of CTx before
6 months), state 5: Late discontinuation (discontinuation of
CTx between 6 and 12 months), state 6: LR only and alive
(intermediate state), state 7: DM only or both DM and LR
and alive (intermediate state) and state 8: Death. Death is
the absorbing state, implying no paths go out from that
state. Each of the possible transitions from one state to an-
other is indicated by an arrow.
The transitions between state 1 and 2, and between state
2 and 3 are of a special nature since their timing is not
random, but deterministic: all patients still in the state at 6
and 12 months, respectively, make the transition at that
moment. The reason for nevertheless creating these three
different states is that it allows to estimate different covari-
ate effects for the transitions originating from state 1 to 3,
thus offering an attractive way to deal with time-
dependent covariate effects. For a similar reason, two sep-
arate discontinuation states have been created.
For discontinuation of CTx, only the period was avail-
able (0–6 weeks, 6 weeks–3 months, 3–6 months, 6–
9 months, 9–12 months). Midpoint imputation was ap-
plied for these transitions. Patients who discontinued
CTx because of LR or DM made a direct transition to
states 6 and 7, to avoid creating a spurious relationship
between discontinuation and adverse events.
The impact of age, BMI, gender, UICC stage, tumor
grade, therapy randomization arm and type of operation
was assessed by means of multi-variable Cox proportional
hazards regression models for all transitions separately.
Covariate impact was neither modelled for the 11 transi-
tions with 20 events or less both because not enough in-
formation was available and because of the lower
relevance of these rare transitions, nor for the two deter-
ministic transitions. The other 8 transitions had a median
number of 54 observed events (range 21–150). A two-
sided p-value < 0.05 was considered statistically significant.
However, because of the large number of tests involved
and the relatively limited number of events for some tran-
sitions, all tests should be considered as exploratory.
Dynamic prediction
We defined a low and high risk patient with different
constellations of risk factors and predicted their out-
comes from commencement of CTx based on the results
of the multi-state analysis. We also obtained dynamic
(updated) predictions of survival probabilities at a fixed
point in time after surgery for patients with the same
sets of covariates and a given set of post-surgery events
as described by Putter et al., 2007 [3].
Results
The multi-state model
A total of n = 471 patients (59.2% of the original dataset)
were included in the multi-state analysis (Additional file 1:
Appendix A, Figure A2, A3). Clinical and pathological char-
acteristics are summarized in Table 1. In a total of 215 pa-
tients (45.6%), tumor recurrence was observed during
follow-up: 157 patients (73%) developed DM, 33 (15.4%)
LR and 25 (11.6%) both LR and DM. The number of pa-
tients does not equal the number of metastases because
one patient could have metastases in different locations. In
particular of the 215 patients who were diagnosed with a
recurrence, 145 had a single tumor localization, 55 two, 12
three and 3 patients had four tumor localizations
(Additional file 1: Appendix B, Table B1).
Figure 1 shows the distribution of the patients at
the end of the follow-up in the msm. A total of 266
patients (56.5%) were censored. Death of 205 patients
(43.5%) was observed during the follow-up time. 276
(58.6%) patients completed the 12 months CTx. Rea-
sons for discontinuation of CTx for the remaining
195 patients (41.4%) were: death within 12 months
from the beginning of CTx in absence of other events
(4 patients), development of LR, DM or both (74 pa-
tients), toxicity (23 patients), request of the patient
(68 patients), a combination of side effects and re-
quest of patient (7 patients), the development of a
second tumor other than colorectal (2 patients), other
reasons (8 patients), unknown reason (9 patients).
The regression models for the transition hazards
yielded the following results, which are entirely reported
in Table 2. A patient with tumor stage UICC IIIc has a
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higher risk to develop distant metastasis (DM) or both
DM and local recurrence (LR) (state 7) than a patient in
stage UICC II if he/she discontinues chemotherapy
within 6 months (state 4) or between 6 and 12 months
(state 5), as well as after the completion of 12 months
CTx (state 3) with HR 3.55 (95%-Confidence Interval
(CI) [1.16; 10.86], p = 0.026), 5.33 (95%-CI [2; 14.19],
p = 0.001) and 3.37 (95%-CI [1.82; 6.23], p < 0.001),
respectively. This patient also has a higher risk to die
after the development of DM or both DM and LR (HR
1.72, 95%-CI [1.08; 2.75], p = 0.023).
Patients who underwent anterior resection have a
63% risk reduction to develop DM or both DM and
LR in comparison to patients who underwent an
abdominoperineal amputation (HR 0.37, 95%-CI [0.19;
0.72], p = 0.003) after late discontinuation. After de-
velopment of LR (state 6) a woman has a 4.62 higher
risk to die (state 8) in comparison to a man (HR
4.62, 95%-CI [1.538;13.890], p = 0.006). Similar effects
of gender could not be observed for other transitions
in our model. In absence of statistical significance,
there is a trend that the combination-CTx schemata
5-FU/FA and 5-FU/IFN-alpha seem generally to be
more effective than 5-FU alone in most transitions.
Prediction based on the msm
On the basis of the results of the msm, the estimated
transition probabilities from commencement of CTx
(when all patients are in state 1) can be calculated
for reference patients. For illustrational purposes, we
defined a high risk patient (tumor stage UICC IIIc,
tumor grade 3–4, CTx 5-FU alone) and a low risk pa-
tient (tumor stage UICC II, tumor grade 1–2, CTx 5-
FU + FA). Both patients are male, 61 years of age at
the beginning of CTx, have a normal BMI of 25 and
underwent anterior resection. Transition probabilities
are represented in Fig. 2 a, b. Figures clearly show
that the high risk patient has, for example, a higher
death probability and the low risk patient has a
higher probability to complete the 12 months CTx
schema and to remain in that state.
Dynamic prediction of 5-year survival probabilities
We again considered the high and low risk reference
patients and we were interested in the dynamic predic-
tion of 5-year survival probabilities. We checked how
these predicted probabilities change as more information
about intermediate events becomes available in the
course of time. In particular we studied how 5-year sur-
vival probabilities changed when both patients stop CTx
at 8 months and experience a DM 1 year after beginning
the CTx and how the same probabilities changed when
they complete the 12 months CTx schema and then
develop DM 2 years after start of CTx.
The plots show the 5-year survival probabilities for the
high and low risk patient based on their history as
described above (Figs. 3 a, b and 4 a, b). Regarding the
first medical history example we can see in Fig. 3a that
the high risk patient has an estimated 5-year survival
probability of 43% (SE 0.07) at the beginning of CTx
based only on his risk factor profile. This probability
decreases dramatically to 11% (SE 0.05) at time t = 1 year
(the moment at which he develops DM). At the same
time (1 year) this probability would have been about
29% (SE 0.10) if he would not have developed DM. In
Fig. 3b we show that the 5-year survival probability of
the low risk patient is 79% (SE 0.04) at the beginning of
CTx based only on his risk factor profile. This probabil-
ity decreases to 21% (SE 0.09) when he develops DM,
10% better than the prognosis of the high risk patient.
This probability would have been 84% (SE 0.05) if he
would not have developed DM but had discontinued
CTx at 8 months. Although the low risk patient seems
to have a better survival probability with a less than
12 months lasting CTx in comparison to a 12 months
lasting CTx, the curves in this study are too close to
conclude that 6 m < CTx < 12 m is better than CTx =
12 months. 95%-CIs are also overlapping (Additional file
1: Appendix B, Table B2). Figures 4a and b show the
Table 1 Summary of patients’ clinical and pathological
characteristics
Variable Median [range] n (%)
Age 62 year [29–85]





5-FU alone 166 (35.2)
5-FU + FA 175 (37.2)







1 + 2 349 (74.1)
3 + 4 122 (25.9)
Operation type
Abdominoperineal amputation 163 (34.6)
Anterior resection 308 (65.4)
The table describes characteristics of the subgroup of patients included in the
multi-state analysis (n = 471)
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survival probabilities of the two reference patients after
completing the 12 months CTx schema and the develop-
ment of a DM. The high risk patient (Fig. 4a) has a 5-
year survival probability of 20% (SE 0.09) at the moment
at which he develops DM. At the same time (2 years)
this probability would have been about 76% (SE 0.08) if
he would not have developed the DM but completed the
CTx schema. In Fig. 4b we observe that the 5-year
survival probability of the low risk patient is 33% (SE
0.13) when he develops the DM 2 years after start of
CTx. By the completion of 12 months CTx in absence of
a DM the survival probability from t = 2 years would
have been 91% (SE 0.03).
Discussion
Multi-state models are an extension of standard survival
analysis, where standard survival models measure the time
span from some time origin until the occurrence of the
event of interest but fail to give information when the
analyzed process involves more than one type of event [3].
So far most applications of multi-state models can be
found in the field of hematological malignancies, in
particular for the analysis of outcomes after hematopoietic
stem cell transplantation, an intervention associated with
many disease- and treatment-related events and therefore
very suitable for multi-state modelling [16–19]. In the field
of solid tumors, less applications of multi-state models can
be found. Putter et al. 2006 [1] used a multi-state model to
analyze survival data from women with breast cancer.
Conlon et al. used a multi-state model with an incorpo-
rated cured fraction for recurrence to jointly model time
to recurrence and time to death in colon cancer [20, 21].
The authors considered a total of 13,938 subjects from 12
randomized phase III adjuvant trials of locally advanced
colon cancer and used a Bayesian Markov-Chain-Monte-
Carlo (MCMC) technique to estimate the parameters of
the multi-state cure model, like those of the Weibull
model for each of the hazard rates, covariate effects for
each of the hazard models and covariate effects in the
logistic model for the probability of cure [20]. In a second
publication, the same authors explore different ways in
which the information about recurrence time and the
assumptions in the multi-state model with an incorporated
cured fraction for recurrence can lead to improved
efficiency. Estimates of overall survival and disease-free
survival can be derived directly from the model with effi-
ciency gains obtained as compared to Kaplan-Meier esti-
mates [21]. Other applications are described by Andersen
et al. [22] who use a multi-state model for bleeding
episodes and mortality in liver cirrhosis and by Mitchell et
al. who show the application of a multi-state model for
urinary tract infections [23].
Cancer history is maybe the best domain for the
application of multi-state models in the medical field.
From diagnosis, the patient can experience different
events, such as surgical treatment, CTx, LR, or DM,
Fig. 1 Graphical representation of the multi-state model. A total of 471 patients entered the model. A total of eight states are included: event-free and
alive after beginning the CTx, alive after at least 6 months CTx but less than 12, event-free and alive after the completion of the 12 months CTx schema,
discontinuation of CTx before 6 months without further events, discontinuation of CTx between 6 and 12 months and no further events, LR only and alive,
DM only or LR and DM and alive, death. The number within each state indicates the number of patients in that state at the end of follow-up. For example
at the moment of censoring 0 patients were in state 1 and 2 and 32 in state 7. Arrows indicate the transitions from one state to another. Numbers in ()
next to the arrows indicate the transition number. Numbers next to the arrows indicate the number of patients experiencing each transition. For
examples 276 patients move from state 2 to state 3 and 150 patients move from state 7 to state 8. LC: local recurrence. DM: distant metastasis
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which alter the survival probability. By better knowing
the probability of having a certain event (e.g. to de-
velop DM or LR) after the primary event (e.g. surgery
for rectal cancer) in the specific case of a patient with
known baseline covariates and by knowing the time
at which the prediction should be done, it is possible
to adapt the follow-up examinations to the risk pro-
file of that patient.
Multi-state models offer several advantages with
respect to more commonly used methods in survival
analysis. The models are more flexible than Cox models
with time-dependent covariates since they allow
Table 2 Hazard Ratios for transitions in the multi-state model
Transition From begin of CTx to ED From begin of CTx to
both LR and DM or DM only
From 6 < CTx < 12 to LD From CTx = 12 to both
LR and DM or DM only
A
Risk factor Categories HR (95%CI) p HR (95%CI) p HR (95%CI) p HR (95%CI) p
Age (per 10 yrs) 0.91 (0.69; 1.2) 0.512 1.06 (0.69; 1.62) 0.794 1.05 (0.81; 1.36) 0.709 1.03 (0.79; 1.34) 0.821
Gender male 1 1 1 1
female 1.47 (0.9; 2.4) 0.125 1.72 (0.8; 3.71) 0.167 0.69 (0.43; 1.13) 0.142 0.81 (0.5; 1.31) 0.396
Grading 1 + 2 1 1 1 1
3 + 4 0.78 (0.42; 1.45) 0.431 2.03 (0.9; 4.58) 0.089 1.28 (0.78; 2.08) 0.331 0.86 (0.5; 1.48) 0.59
UICC Stage II 1 1 1 1
IIIa 1.42 (0.65; 3.1) 0.381 0.49 (0.06; 4.16) 0.516 0.74 (0.3; 1.79) 0.499 1.31 (0.55; 3.15) 0.544
IIIb 1.06 (0.57; 1.98) 0.846 1.05 (0.33; 3.3) 0.94 1.14 (0.66; 1.98) 0.643 2.38 (1.31; 4.35) 0.005*
IIIc 1.01 (0.52; 1.98) 0.969 2.16 (0.78; 6.03) 0.14 1.56 (0.9; 2.7) 0.116 3.37 (1.82; 6.23) < 0.001*
BMI (per kg/m2) 0.99 (0.93; 1.06) 0.831 0.92 (0.83; 1.02) 0.116 0.98 (0.92; 1.04) 0.467 1 (0.94; 1.06) 0.982
Adjuvant CTx 5-FU 1 1 1 1
5-FU + FA 1.01 (0.54; 1.88) 0.982 0.72 (0.31; 1.69) 0.452 1.12 (0.68; 1.86) 0.661 0.92 (0.55; 1.53) 0.747
5FU + IFN- α 1.66 (0.92; 3.02) 0.094 0.6 (0.21; 1.71) 0.34 1.38 (0.8; 2.4) 0.25 0.96 (0.54; 1.72) 0.886
Operation type Abd. 1 1 1 1
amp.Anterior res. 0.81 (0.49; 1.33) 0.4 0.72 (0.33; 1.6) 0.424 1.04 (0.66; 1.62) 0.874 0.79 (0.5; 1.24) 0.307
B
Transition From ED to both LR and
DM or DM only
From LD to both LR and DM
or DM only
From LR to death From both LR and DM or
DM only to death
Risk factor Categories HR (95%CI) p HR (95%CI) p HR (95%CI) p HR (95%CI) p
Age (per 10 yrs) 1.01 (0.66; 1.53) 0.977 0.86 (0.58; 1.28) 0.462 1.85 (0.91; 3.76) 0.089 1.16 (0.96; 1.4) 0.125
Gender male 1 1 1 1
female 0.88 (0.34; 2.3) 0.794 0.95 (0.42; 2.14) 0.894 4.62 (1.54; 13.89) 0.006* 1.2 (0.83; 1.73) 0.325
Grading 1 + 2 1 1 1 1
3 + 4 0.9 (0.32; 2.59) 0.85 1.28 (0.64; 2.56) 0.478 1.43 (0.32; 6.38) 0.636 1.07 (0.73; 1.55) 0.737
UICC Stage II 1 1 1 1
IIIa 0.63 (0.07; 5.34) 0.672 1.12 (0.21; 5.86) 0.891 0.91 (0.19; 4.44) 0.907 1.09 (0.52; 2.28) 0.815
IIIb 1.37 (0.4; 4.66) 0.616 2.65 (0.97; 7.25) 0.059 0.76 (0.18; 3.22) 0.705 1.18 (0.72; 1.93) 0.516
IIIc 3.55 (1.16; 10.86) 0.026* 5.33 (2; 14.19) 0.001* 2.82 (0.54; 14.86) 0.221 1.72 (1.08; 2.75) 0.023*
BMI (per kg/m2) 0.94 (0.83; 1.07) 0.356 0.94 (0.84; 1.06) 0.306 0.94 (0.83; 1.05) 0.265 0.97 (0.93; 1.02) 0.208
Adjuvant CTx 5-FU 1 1 1 1
5-FU + FA 2.4 (0.78; 7.33) 0.126 0.53 (0.25; 1.13) 0.102 0.91 (0.23; 3.5) 0.885 1.29 (0.88; 1.88) 0.186
5FU + IFN-α 0.66 (0.19; 2.36) 0.524 0.82 (0.35; 1.91) 0.639 0.69 (0.25; 1.96) 0.491 1.28 (0.82; 2) 0.284
Operation type Abd. amp. 1 1 1 1
Anterior res. 0.67 (0.25; 1.77) 0.417 0.37 (0.19; 0.72) 0.003* 0.74 (0.23; 2.41) 0.618 0.85 (0.6; 1.21) 0.37
*Result statistically significant at a 2-sided p-value < 0.05
Hazard Ratio, 95% Confidence Interval and p-value for each covariate and each transition with more than 20 events (ED Early discontinuation, LD Late discontinuation,
CTx chemotherapy, LR local recurrence, DM distant metastasis, CI confidence interval)
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different baseline hazards for different transitions. They
are more comprehensive than landmark models since all
prediction timepoints are included in a single model and
since sequences of events can also be analyzed. A major
advantage compared to both of these methods is that the
model yields estimates of probabilities of being in both
intermediate and absorbing states. In our model, e.g., we
can consider the relevance of predictions starting from any
of the states indicating treatment discontinuation by asses-
sing the chance that a patient with certain characteristics
really is in such a state at different moments after start.
We designed a msm with eight states with the aim to
investigate the effect of the covariates on the different
transitions from one state to the other and the role of
intermediate events in affecting the survival probability
of the patients. For applying standard formulas and soft-
ware to estimate the quantities of interest, it had to be
assumed that the model is Markovian, i.e., that the prog-
nosis for a patient at a certain moment depends on the
state where he/she is at that moment, and not on the
states previously visited or the duration in the current
state. By creating two CTx states instead of one and two
discontinuation states, we managed to include informa-
tion about the patients’ histories (length and possible
discontinuation of CTx) and assessing the differential
impact of risk factors on subsequent transitions, while
still keeping the attractive statistical properties of the
Markov model and the possibility to fit the model with
the ‘mstate’ package. It must be noted, however, that the
states 6 < CTx < 12 and CTx = 12 are not, like the other
Fig. 2 a, b: Stacked transition probabilities. Transition probabilities starting from state 1 - begin of CTx - at t = 0 for the high risk patient (a) and
for the low risk patient (b) as defined in the results section. The term ´stacked´ means that all transition probability curves are plotted on top of
each other; the difference between 2 curves indicates the transition probability from state 1 to the state with the name written between the
curves. States 1 and 2 have been merged to one state ‘CTx < 12’ (meaning under treatment with CTx) since the transition between them does
not represent an event with a clinical meaning
Fig. 3 a, b Dynamic prediction of 5-year survival. The plots show time-dependent predictions of survival at 5 years after commencement of CTx for
the high risk patient (a) and for the low risk one (b) after discontinuation of CTx at 8 months and the development of a DM at 1 year after start of CTx.
Dashed curves indicate what the 5-year survival probability would have been without further intermediate events (discontinuation of CTx, DM)
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states, characterized by an event that makes the patient
experience a transition, but only by the passing of time;
they are thus more relevant for model fitting than for
describing clinical histories. Other approaches exist in
which time-dependent effects of the history of the pa-
tients can be modelled without categorizing time.
A weakness of the current study is that for some of
the transitions the exact transition times were not avail-
able. For discontinuation of CTx, only the period was
given in the data. This event should in principle have
been treated as interval-censored and be analyzed by a
method suitable for this kind of data. However, to re-
main within the semi-parametric framework of our
model, we used a pragmatic approach by applying mid-
point imputation. In addition, time-to-event data regard-
ing the development of LR, DM or both LR and DM
were recorded in the original study in only 3 categories:
LR, DM or both LR and DM. For the patients in this last
category only the date of the second of these two events
(LR or DM) was recorded. According to the current lit-
erature which states that in case of simultaneous LR and
DM the prognosis is defined by the DM [24, 25], we de-
cided to create one state named ´DM or both LR and
DM´. Of a total of 182 patients who entered this state,
only 25 (13.7%) were categorized in the original study by
the presence of both DM and LR. Time intervals be-
tween LR and DM or viceversa were not available for
these patients, implying the exact moment when they
entered the LR or DM state is unknown. Since this only
affects 25 patients and since this time interval will have
been short for some of them, we assume that the impact
of this missing data on the estimated probabilities is lim-
ited. In addition, information about a possible second
operation to treat the LR and/or the DM, which could
be represented as an additional state in our model since
it may have affected the prognosis of the patients, was
also not recorded in the original study.
In the current study, 40% of patients had to be excluded
from the multi-state analysis. Also in other contexts, the
lack of detailed data describing risk factors and the course
of the disease for larger groups of patients is an impedi-
ment to the development of relevant and accurate multi-
state models. Therefore, a major goal of the current study
is to illustrate some of the features of multi-state models
to advocate their use and to improve data collection to
this end. For example, the multi-state model helps to
zoom in on the differential impact of the three CTx regi-
mens on different endpoints. This information cannot be
retrieved by the primary analysis of the trial.
In accordance with current literature we found that
patients with higher tumor stage and/or grade have a
higher risk to develop DM both after early and late
discontinuation of CTx and after completion of
12 months of CTx [26]. Interesting is the result regard-
ing the worse survival prognosis of women after the
development of LR compared to that of men. However,
this finding may be partly due to chance because of the
low number of events in this transition (n = 26). For
this reason we considered both the poor and good risk
reference patient to be male. No specific literature ex-
ists regarding how gender affects survival after the de-
velopment of LR or DM. One publication dealing with
gender [27] aimed to investigate the association of gen-
der and age with acute toxicity after radio-
chemotherapy for UICC II/III rectal cancer. Although
women showed higher hematologic (p < 0.001) and
acute organ toxicity (p < 0.001) in comparison to men,
the authors found a trend toward higher 10-year overall
survival in women (62.7% vs. 58.4%, p = 0.066). By ana-
lyzing our data stratified for gender (by the Kaplan-
Fig. 4 a, b Dynamic prediction of 5-year survival. The plots show time-dependent predictions of survival at 5 years after commencement of CTx
for the high risk patient (a) and for the low risk one (b) after the completion of the 12 months CTx and the development of a DM 2 years after
start of CTx. Dashed curves indicate what the 5-year survival probability would have been without DM
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Meier method), we found similar survival in women
and men (log-rank test, p = 0.85).
Patients that underwent an abdominoperineal amputa-
tion have a higher risk to develop DM or both DM and
LR. It is known and has been shown in several studies
that a higher incidence of LR after abdominoperineal re-
section occurs compared to low anterior resection [28].
In fact, patients who need this type of surgery have a
tumor which is locally advanced and most likely muscle
infiltrating, which makes the accomplishment of a rad-
ical resection difficult, increasing the possibility of the
development of LR due to remaining tumor tissue or
cells after the operation [28]. Kornmann et al. reported
in 2010 a 5-year recurrence-free survival rate for locally
advanced rectal cancer of 60.4% (95% CI [55%–65.4%])
after anterior resection vs. 46.2% (95% CI [38.6%–
53.5%]) after abdominoperineal amputation (p = 0.005)
[29]. We could not demonstrate a higher risk to develop
LR with this type of operation in our data. However, as
previously described, we have not enough sample size in
the transitions into the state LR. Finally, none of the risk
factors included in the models was significantly associ-
ated with discontinuation of CTx.
Based on the results of the msm analysis and on
current literature [14, 24–26, 30] we defined a high and
low risk reference patient based on the baseline covari-
ate profile, representing well the patients in the dataset.
The graphical illustrations of the 5-year predicted
probabilities answer immediately the question about the
relevance, in term of survival probabilities, of each event
in the clinical history of the patient allowing the adjust-
ment of the survival probabilities in the course of time.
In fact, dynamic prediction allows the estimation of sur-
vival probabilities of a patient at each point in time tak-
ing into consideration all new events which take place.
Additionally we showed how different combinations of
covariates (high and low risk patient) define from the be-
ginning the survival probability. Generally the prognosis
got worse for all patients when they experienced DM,
even if the 5-year-survival probability of survival for the
low risk patient was higher than that of the high risk
one, 21% vs. 11% at 1 year and 33% vs. 20% at 2 year
after start of CTx, respectively.
The question about a possible correlation between
duration of CTx, risk factor profile and survival prob-
ability in locally advanced rectal cancer remains open
and more studies are needed. In fact, regarding the low
risk patient we observed that the survival curves repre-
senting 5-year survival probability with late discontinu-
ation vs. CTx = 12 are too close to each other to
conclude that 6–12 months CTx is better than
12 months. The actual guidelines for locally advanced
rectal cancer (UICC II and III) in absence of any neoad-
juvant treatment, as was the case for the patients
included in the FOGT-2 study, suggest a 6 months long
adjuvant radio-chemotherapy with 5FU or Capecitabine
[21, 22].. We defined consequently in our multi-state
model the three groups: CTx duration < 6 months, CTx
duration between six and 12 months according to the
recommendations of the S3 guidelines, CTx duration of
1 year according to the study protocol.
One promising field which is gaining more and more
interest regarding response prediction to CTx is gene ex-
pression profiling [31, 32]. In a recent study published in
2015 [33], a gene expression profile was developed
which was able to predict treatment response in CRC
patients treated with standard CTx regimens. Indeed,
patients with a favourable gene expression profile had a
higher response rate (58% vs. 13%, p = 0.024),
progression-free survival (61% vs. 13% at 1 year, HR =
0.32, p = 0.009) and overall survival (32 vs. 16 months,
HR = 0.21, p = 0.003) than patients with an unfavourable
predictive signature. Future studies should consider also
this variable as important prognostic factor.
One partial limitation regarding the routine use of
msm in surgical research is the complexity of the com-
puter program needed for such an analysis. However
very good tutorials are freely available online and explain
the procedure in detail [2, 3]. Our aim was to illustrate
an intuitive application of a multi-state model in the
medical field with an immediate and concrete answer to
the question about survival probability given a particular
medical history of a patient. We think it is important to
introduce multi-state models in the medical field in a
way which is understandable for clinicians.
Conclusion
In conclusion, multi-state models are a promising tool
also in surgical research as they help to gain additional
insight in the complex events after start of treatment
and to extract more information from trial data. Risk
factor profile defines from the beginning the prognosis
of the patient. By using dynamic prediction, it is possible
to adjust the prognosis in course of time by incorporat-
ing any type of information regarding the disease devel-
opment and treatment options (intermediate events) in
the clinical history of the patient. This allows the cre-
ation of treatment algorithms for each possible disease/
recovery process, which can simplify the decision mak-
ing process and allow a better risk-benefit calculation.
Additional file
Additional file 1: Appendix A. This file contains an introduction about
multi-state models as well as the graphical representation of the model
we used for the analysis of the data. Additionally, a flow-chart illustrates
the procedure for the selection of the patients who could be included in
the analysis together with a landmark analysis to assess the likelihood of
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informative missing. Appendix B Table 1b illustrates the localization of tumor
recurrence and Table B2 shows the 5-year survival probability with 95%-CI at
different timepoints after start of CTx both for Late discontinuation and for
CTx = 12 m for the low risk patient. (PDF 120 kb)
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